Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Leonel, Hernandez-Aya"'
Autor:
Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM wit
Externí odkaz:
https://doaj.org/article/b89b2a51187f4158bed6c6e774c8ce00
Autor:
Leonid Shmuylovich, MD, PhD, Aubriana M. McEvoy, MD, MS, Ryan C. Fields, MD, Leonel Hernandez-Aya, MD, George Ansstas, MD, David Y. Chen, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 29, Iss , Pp 131-133 (2022)
Externí odkaz:
https://doaj.org/article/d8801dba21884d899ff85dcdd8d0b159
Autor:
Jairam Krishnamurthy, Jingqin Luo, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Anna Roshal, Pavan K. Tandra, Mathew Cherian, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Mattias Bergqvist, Lindsey Peterson, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim t
Externí odkaz:
https://doaj.org/article/66f1f8841c624feda0766f004e302bc2
Autor:
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the
Externí odkaz:
https://doaj.org/article/2021304222154fa1af9d43a174d21c40
Autor:
Joseph Sacco, Richard Carvajal, Omid Hamid, Marcus Butler, Jason Luke, Takami Sato, Paul Nathan, Jessica Hassel, Douglas Johnson, Leonel Hernandez-Aya, Alexander Shoushtari, Josep Piulats, Enrique Espinosa, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Michelle McCully, Shaad Abdullah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7ed3173927ef4914952b41123e9dc8f8
Autor:
Omid Hamid, Brendan Curti, Craig L Slingluff, Mohammed Milhem, Jose Lutzky, Suthee Rapisuwon, Brian Gastman, Takami Sato, Marcus O Butler, Robert Andtbacka, Eddy Hsueh, Robert Weber, John Glaspy, Sekwon Jang, Sajeve Thomas, Karl D Lewis, Leonel Hernandez-Aya, John Hyngstrom, Adam Berger, Edward Levine, Montaser F Shaheen, Vinay Gupta, Svetomir N Markovic, Tawnya Bowles, Joel Claveau, Prejesh Philips, Shernan G Holtan, William Schmidt, Juan Paramo, Arvinda Padmanabhan, Daniel Milton, Andrew Pecora, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Peter Beitsch, Edward C McCarron, Deepti Behl, Brent Blumenstein, Joanna J Peterkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/5160c99c6dc74e998f952d3b03d4f787
Autor:
Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Publikováno v:
Cancer Research. 83:P3-06
Background: Neoadjuvant immune checkpoint inhibition (ICI) in combination with chemotherapy is approved for patients with high-risk, early-stage triple-negative breast cancer (TNBC) based on improved outcomes in the KEYNOTE-522 trial. However, some p
Autor:
Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/657146515d294ae39d54d915d166a66e
Autor:
Thomas Eigentler, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Claas Ulrich, Brian Stein, Jessica L Geiger, Emmanuel Okoye, Melissa Mathias, Jocelyn Booth, Siyu Li, Matthew G Fury
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and th
Externí odkaz:
https://doaj.org/article/a6c7cd3cc4a44c238d9eeebc62a5df0f
Autor:
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/d43d6cb5eed04adbaa9c7c0324c11d5c